The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis

Investigational New Drugs

Volumn 25, Issue 2, 2007, Pages 95-105

  Jin, Jing ^a,b   Sun, Hua ^a   Wei, Huailing ^a   Liu, Gengtao ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Apoptosis; DDB; Multidrug resistance; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; BROMINE DERIVATIVE; CASPASE 3; DIMETHYL 4,4' DIMETHOXY 5,6,5'6' DIMETHYLENE DIOXYBIPHENYL 2,2' DICARBOXYLATE; DIMETHYLTHIAZOLYL 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DOXORUBICIN; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; LIVER PROTECTIVE AGENT; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASSAY; BLOOD TOXICITY; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; FLUOROMETRY; HEPATITIS B; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; MOUSE; MULTIDRUG RESISTANCE; NASOPHARYNX CARCINOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; TUMOR XENOGRAFT;

ANEMIA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL MEMBRANE; DICARBOXYLIC ACIDS; DNA; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS; FEMALE; FLOW CYTOMETRY; HEPATITIS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, NUDE; P-GLYCOPROTEIN; PHENOTYPE;

EID: 33845880643     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9001-z     Document Type: Article

References (29)

1. Gottesman MM (2002) Mechanisms of cancer drugs resistance. Annu Rev Med 53:615-627
2. Thomas H, Coley H (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159-165
3. Fojo T, Bates S (2003) Strategies for reversing drug resistance. Oncogene 22:7512-7523
4. Liscovitch M, Lavie Y (2002) Cancer multidrug resistance: A review of recent drug discovery research. IDrugs 5:349-355
5. Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T (2001) A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer 95:1577-1590
6. Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, Ziessman H, Atkins F, Hawkins MJ (2001) Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 19:3130-3141
7. Lee CH (2004) Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). Curr Med Chem Anti-Canc Agents 14:43-52
8. Liu GT, Wang GF, Wei HL, Bao TT, Song ZY (1979) A comparison of the protective actions of biphenyl dimethyl-dicarboxylate, transstilbene, alcoholic extracts of Fructus Schizandrae and ganoderma against expeimental liver injury in mice. Yao Xue Xue Bao 1:598-604
9. Liu GT, Wei HL, Song ZY (1982) Further studies on the protective action of biphenyl dimethyl-dicarboxylate (BDD) against experimental liver injury in mice. Yao Xue Xue Bao 17:101-106
10. Wang GX, Ben CE, Ye BK (1988) Reparative effects of biphenyl dimethyl dicarboxylate on experimental liver injury in rats with histochemical and electronmicroscopy study. Zhong Xi Yi Jie He Za Zhi 8:158-160
11. Liu GT (1983) From the study of Fructus schizandrae to the discovery of biphenyl dimethyl-dicarboxylate. Yao Xue Xue Bao 18:714-720
12. Liu Z, Cui Q, Fu T, Liu G (1996) Inducing effect of dimethy-4, 4′-dimethoxy-5, 6,5′,6-dimethylenedioxybipheny-2, 2′-dicarboxylate (DDB) on differentiation of leukemia HL-60 cells. Zhonghua Yi Xue Za Zhi 76:214-217
13. Liu Z, Liu G, Zhang S (1996) Reversing effect of dimethyl-4,4′- dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′- dicarboxylate (DDB) on the phenotypes of human hepatocarcinoma cells line. Cancer Lett 108:67-72
14. Jin J, Wang FP, Wei H, Liu G (2005) Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol 55:179-188
15. Huang M, Liu G (1999) The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett 135:97-105
16. Labroille G, Belloc F, Bilhou-Nabera C, Bonnefille S, Bascans E, Boisseau MR, Bernard P, Lacombe F (1998) Cytometric study of intracellular P-gp expression and reversal of drug resistance. Cytometry 32:86-94
17. Heyworth CM, Gagen D, Edington KG, Fairbairn LJ (2002) Retroviral transfer and expression of human MDR-1 in a murine haemopoietic stem cell line does not alter factor dependence, growth or differentiation characteristics. Leukemia 16:106-111
18. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z (1993) The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 53:3186-3192
19. Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ, Huang P (2003) Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278:37832-37839
20. Feng WH, Wei HL, Liu GT (2002) Effect of PYCNOGENOL on the toxicity of heart, bone marrow and immune organs as induced by antitumor drugs. Phytomedicine 9:414-418
21. Laginha KM, Verwoert S, Charrois GJ, Allen TM (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 11(19 Pt 1):6944-6949
22. Simstein R, Burow M, Parker A, Weldon C, Beckman B (2003) Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med 228:995-1003
23. Grossi A, Biscardi M (2004) Reversal of MDR by verapamil analogues. Hematology 9:47-56
24. Lage H (2003) ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22:188-199
25. Kim H, Barroso M, Samanta R, Greenberger L, Sztul E (1997) Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells. Am J Physiol 273:X687-X702
26. Ferrao P, Sincock P, Cole S, Ashman L (2001) Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia. Leuk Res 25:395-405
27. Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW (2004) Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ 11:1028-1037
28. Mimnaugh EG, Fairchild CR, Fruehauf JP, Sinha BK (1991) Biochemical and pharmacological characterization of MCF-7 drug-sensitive and AdrR multidrug-resistant human breast tumor xenografts in athymic nude mice. Biochem Pharmacol 42:391-402
29. Vickers PJ, Dickson RB, Shoemaker R, Cowan KH (1988) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Mol Endocrinol 2:886-892